Women Who Have Precancerous Lesions Removed Have Increased Risk Of Developing Cervical, Vaginal Cancer For At Least 25 Years, Study Says
Main Category: Cervical Cancer / HPV VaccineAlso Included In: Women's Health / Gynecology; Cancer / Oncology
Article Date: 30 Oct 2007 - 0:00 PDT
| Patient / Public: | ![]() |
4.83 (6 votes) |
| Healthcare Prof: | ![]() |
3 (2 votes) |
Women who have precancerous lesions removed from their cervix are at an increased risk of developing cervical or vaginal cancer during the 25 years after the procedure, according to a study published on Friday in BMJ, Reuters reports.
For the study, Bjorn Strander of Sahlgren's Academy at the University of Gothenburg and colleagues examined records from the National Swedish Cancer Register of more than 132,000 women diagnosed with precancerous lesions from 1958 to 2002. The researchers found 881 women had developed cervical cancer and 111 women had developed vaginal cancer more than one year following their diagnosis, even after they had the lesions removed (Kahn, Reuters, 10/25). According to the researchers, women with cervical lesions were more than twice as likely to develop invasive cancer of the cervix, compared with the general female population. A woman's risk of cancer increased if she was older at the time of diagnosis, particularly among women ages 50 or older, the study found. Women with severe lesions were almost seven times as likely to develop cancer, compared with the general population; however, the risk decreased threefold 25 years after treatment, the study found (AFP/Yahoo! News, 10/25).
The findings underscore the need for follow-up tests to continue for at least 25 years after treatment, Strander said, adding, "This is a warning to the health care system to keep track of these women." The reason the risk remains high has not been investigated, "but there are indications it could be because a lack of surveillance," Strander said, adding, "The risk is quite steady. It does not decrease." In a related BMJ editorial, researchers wrote that the findings show current testing guidelines are not sufficient and that further study is necessary. "One clear indication is that women treated for (severe precancerous lesions) should continue surveillance beyond the age limit of regular screening," the editorial says (Reuters, 10/25).
The study is available online.
The related editorial also is available online.
Reprinted with kind permission from http://www.kaisernetwork.org. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at http://www.kaisernetwork.org/dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork.org, a free service of The Henry J. Kaiser Family Foundation© 2005 Advisory Board Company and Kaiser Family Foundation. All rights reserved.
Visit our cervical cancer / hpv vaccine section for the latest news on this subject.
MLA
16 Feb. 2012. <http://www.medicalnewstoday.com/releases/87017.php>
APA
http://www.medicalnewstoday.com/releases/87017.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.




